CompletedNCT02672111
Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Addiction
Researchers compared CAM2038 q1w or q4w exposure to SL BPN/NX and CAM2038 q1w or q4w new to BPN treatment, tracking side effects to assess long-term safety in adults with opioid dependence.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared CAM2038 q1w or q4w exposure to SL BPN/NX and CAM2038 q1w or q4w new to BPN treatment, tracking side effects to assess long-term safety in adults with opioid dependence.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Birmingham and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 228
- Sponsor
- Braeburn Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, United Kingdom, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02672111
- Official title
Show the full official title
An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder
Get this study by email
Recruitment & locations
CompletedBirmingham, United States · Haleyville, United States · Hamilton, United States
27 more locations
- Jacksonville, United States
- Maitland, United States
- Fall River, United States
- Belvidere, United States
- Berlin, United States
- New York, United States
- Conshohocken, United States
- Newcastle, Australia
- Norwood, Australia
- Sydney, Australia
- Aarhus, Denmark
- Odense, Denmark
- Heilbronn, Germany
- Kassel, Germany
- Mannheim, Germany
- Regensburg, Germany
- Stuttgart, Germany
- Budapest, Hungary
- Stockholm, Sweden
- Västerås, Sweden
- Tainan, Taiwan
- Taichung, Taiwan
- Taipei, Taiwan
- Fishponds, United Kingdom
- Hellesdon, United Kingdom
- Dundee, United Kingdom
- London, United Kingdom
Questions about this study
What did researchers investigate?
Researchers compared CAM2038 q1w or q4w exposure to SL BPN/NX and CAM2038 q1w or q4w new to BPN treatment, tracking side effects to assess long-term safety in adults with opioid dependence.
Who is behind this study?
The study sponsor is Braeburn Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including CAM2038 q1w or q4w exposure to SL BPN/NX and CAM2038 q1w or q4w new to BPN treatment.
Who was this study for?
Listed age limits: 18 years to 65 years.
